Answers are grounded in this paper and cite their sources.
AL amyloidosis is a fatal systemic amyloid disease in which antibody light chains (LCs), including full-length (FL) and their proteolytically fragmented variable (VL) and constant (CL) domains, aggregate within a complex extracellular matrix (ECM) across multiple tissues. However, how these co-existing species shape aggregation kinetics, fibril morphology, stability, and toxicity remains unexplored. In this work, using a patient-derived LC (AL55), we show that FL transiently interacts with VL, slowing its aggregation nearly four-fold and diverting it into protease-sensitive, seeding-incompetent protofibrillar aggregates rather than mature amyloid assemblies. VL alone or in the presence of inert CL instead matures into toxic, protease-resistant, seeding-competent helical fibrils. Owing to their greater protease resistance and seeding competence, VL-dominated amyloid assemblies persist and contribute to their enrichment within tissues. The FL-mediated redirection is generic across multiple amyloidogenic VLs. These results reveal that LC aggregation, like that of Aβ and Tau, is governed by interplay between full-length and fragmented species, rather than VL domain aggregation in isolation. Overall, this work identifies a molecular basis for the selective enrichment of VL fibrils in patients and provides a therapeutic rationale for stabilizing VL domains to prevent their pathological aggregation.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: